Management of Endometrial Carcinoma

1. Diagnosis and Pretreatment Evaluation

2. Histologic and Molecular Classification

• Type I (~80%): endometrioid, low-grade, estrogen-driven, arising from atypical hyperplasia; PTEN and β-catenin mutations common; generally good prognosis.
• Type II: serous, clear cell; unrelated to estrogen excess, arise from endometrial intraepithelial carcinoma in an atrophic endometrium; TP53, HER2/neu alterations; account for <10% of cases but over half of endometrial cancer deaths (Berek & Novak's Gynecology, p. 2172).

• POLE-mutated (POLEmut) - excellent prognosis, adjuvant therapy can often be omitted even with adverse features.
• Mismatch-repair deficient (MMRd)/MSI-high - intermediate prognosis; relevant for Lynch syndrome screening and immunotherapy eligibility.
• No specific molecular profile (NSMP) - intermediate prognosis.
• p53-abnormal (p53abn) - poor prognosis, behaves aggressively regardless of histologic grade; most serous/clear cell carcinomas fall here.

3. Surgical Staging and Primary Treatment

• Total hysterectomy + bilateral salpingo-oophorectomy, peritoneal cytology, and surgical staging with lymph node assessment (pelvic +/- para-aortic lymphadenectomy or sentinel lymph node mapping, now widely adopted as an alternative to full lymphadenectomy in early-stage disease).
• Minimally invasive (laparoscopic/robotic) surgery is preferred over laparotomy when feasible, with comparable oncologic outcomes and lower morbidity (GOG LAP2 trial).
• Radical hysterectomy does not improve survival over extrafascial hysterectomy + BSO in clinical stage I disease and is not routinely indicated (Berek & Novak's Gynecology, p. 2176).
• Lymph node assessment may be omitted in patients with negligible risk of nodal spread (e.g., low-grade, minimally invasive endometrioid tumors).
• Primary radiation therapy (intracavitary +/- external-beam) is reserved for the 5-15% of patients medically unfit for surgery; disease-specific survival is favorable (85-87% at 5 years) but overall survival is lower due to comorbidity-related mortality.

4. Risk-Stratified Adjuvant Therapy

5. Fertility-Sparing Treatment

6. Advanced, Metastatic, and Recurrent Disease

• Isolated vaginal/pelvic recurrence, no prior radiation: radiotherapy (external pelvic RT + vaginal brachytherapy) achieves 40-80% complete remission in previously unirradiated patients.
• Resectable recurrence in younger patients with well-differentiated tumors, long disease-free interval, and no residual disease after resection: secondary cytoreductive surgery.
• Systemic/metastatic disease: platinum-based chemotherapy (carboplatin/paclitaxel) is the backbone.
• Hormonal therapy (progestins, aromatase inhibitors, tamoxifen) for low-grade, hormone receptor-positive recurrences, particularly in older or comorbid patients.

Major recent practice change - immunotherapy

• Adding pembrolizumab or dostarlimab to carboplatin/paclitaxel, followed by maintenance immunotherapy, significantly improves progression-free survival, with the largest benefit in MMRd/MSI-high tumors (NRG-GY018 and RUBY trials).
• The DUO-E trial showed durvalumab +/- the PARP inhibitor olaparib added to chemotherapy also improves outcomes, particularly in molecular subgroups without MMRd.
• These findings are the basis for 2023-2025 NCCN and ESGO-ESTRO-ESP updates recommending routine mismatch-repair/microsatellite-instability testing to guide first-line immunotherapy eligibility (Bogani et al. meta-analysis, PMID 38431043; Mirza et al. systematic review, PMID 39557140; Picheta et al., PMID 41009360).

Summary of Key Principles

1. Surgery (hysterectomy, BSO, surgical staging +/- sentinel node mapping) is the cornerstone for operable disease.
2. Adjuvant therapy is now risk- and increasingly molecular subtype-driven (POLEmut, MMRd, NSMP, p53abn), not grade/stage alone.
3. Radiation, particularly vaginal brachytherapy, reduces local recurrence but generally does not improve overall survival in intermediate-risk disease; chemotherapy is added for high-risk/high-grade and non-endometrioid histologies.
4. Recurrent and advanced disease management now routinely incorporates immune checkpoint inhibitors combined with chemotherapy, especially in MMRd tumors, representing the biggest shift in management over the past three years.

Management of Endometrial Carcinoma

I. INTRODUCTION

II. ETIOPATHOGENESIS / CLASSIFICATION

1. POLE-mutated (POLEmut) — excellent prognosis
2. Mismatch-repair deficient (MMRd)/MSI-high — intermediate prognosis; screen for Lynch syndrome; predicts immunotherapy benefit
3. No specific molecular profile (NSMP) — intermediate prognosis
4. p53-abnormal (p53abn) — poor prognosis, aggressive course even at low volume

III. CLINICAL FEATURES AND DIAGNOSTIC WORKUP

• Postmenopausal bleeding (cardinal symptom) or abnormal uterine bleeding in perimenopausal women
• Diagnosis: office endometrial (pipelle) biopsy → hysteroscopic biopsy/D&C if inadequate
• Pretreatment workup: pelvic exam, TVS/MRI (assess myometrial invasion, cervical extension), CA-125 (correlates with nodal spread), CT chest/abdomen if high-grade or advanced disease suspected, universal Lynch syndrome screening by MMR IHC/MSI testing (NCCN Category recommendation), molecular subtyping (POLE, p53) where feasible.

IV. STAGING (FIGO — surgical-pathologic)

V. RISK-GROUP STRATIFICATION (Basis of Adjuvant Decision-Making)

VI. MANAGEMENT

A. Surgery (cornerstone of treatment — Category 1, NCCN)

• Approach: Minimally invasive (laparoscopic/robotic) surgery is preferred over laparotomy — equivalent oncologic outcome, lower morbidity (GOG-LAP2).
• Radical hysterectomy is NOT indicated for apparent early disease — no survival benefit over extrafascial hysterectomy, only added morbidity (Berek & Novak's Gynecology, p. 2176).
• Modified radical hysterectomy considered only with gross/biopsy-proven cervical stromal invasion (clinical stage II).
• Ovarian preservation may be considered in select premenopausal stage IA grade 1 endometrioid cancer without a hereditary risk (BRCA/Lynch).
• High-grade histologies (serous, clear cell, carcinosarcoma): full staging including omentectomy and peritoneal biopsies, as with epithelial ovarian cancer protocol.
• Advanced/Stage III-IV: maximal cytoreductive surgery when feasible; palliative hysterectomy for bleeding control if unresectable.
• Patients medically unfit for surgery (5-15%): primary radiotherapy (intracavitary ± EBRT).

B. Adjuvant Radiotherapy

C. Chemotherapy

• Regimen: Carboplatin + Paclitaxel (standard, replacing older cisplatin/doxorubicin regimens; GOG-209 established non-inferiority to TAP).
• Indications: Stage III-IV disease, high-grade/high-risk histology (serous, clear cell, carcinosarcoma), p53abn molecular subtype, or as adjuvant/sandwich therapy with RT in high-risk uterine-confined disease.

D. Hormonal Therapy

• Progestins (megestrol acetate, medroxyprogesterone), aromatase inhibitors, or tamoxifen for low-grade, hormone receptor-positive recurrent/metastatic disease, particularly in older or comorbid patients unfit for chemotherapy.
• Fertility-sparing management (grade 1 endometrioid, stage IA, no myometrial invasion, young patient desiring fertility): high-dose oral progestins or levonorgestrel-IUD ± metformin, with repeat biopsy every 3-6 months; hysterectomy after childbearing complete (Cochrane review 2025, PMID 40626388).

E. Immunotherapy / Targeted Therapy — major recent NCCN update (Category 1)

• Pembrolizumab or dostarlimab + carboplatin/paclitaxel, followed by maintenance immunotherapy, is now NCCN Category 1 first-line therapy for advanced/recurrent disease — benefit is greatest in MMRd/MSI-high tumors (NRG-GY018, RUBY trials).
• Durvalumab ± olaparib (PARP inhibitor) + chemotherapy (DUO-E trial) is an option, particularly benefiting non-MMRd subgroups.
• HER2-directed therapy + chemotherapy is a Category 1 option for HER2-positive uterine serous carcinoma.
• For relapse: NCCN recommends hormone therapy → chemotherapy on progression for low-grade metastatic disease; platinum/taxane chemotherapy (± immunotherapy) for symptomatic, high-grade, or bulky disease.

F. Recurrent Disease

• Isolated vaginal/pelvic recurrence, no prior RT: EBRT + vaginal brachytherapy — 40-80% complete remission if not previously irradiated.
• Resectable recurrence in favorable candidates (long disease-free interval, low-grade tumor, resectable to no residual): secondary cytoreductive surgery.
• Distant/widespread recurrence: systemic therapy as per stage IV algorithm above (chemo ± immunotherapy, or hormonal therapy for low-grade receptor-positive disease).

VII. FOLLOW-UP

VIII. PROGNOSIS

IX. RECENT ADVANCES (for "recent advances" section of exam answer)

1. FIGO 2023 staging integrating molecular classification.
2. Universal molecular classification (POLEmut/MMRd/NSMP/p53abn) as NCCN/ESGO-ESTRO-ESP-endorsed standard for risk stratification.
3. Immune checkpoint inhibitors (pembrolizumab, dostarlimab) added to first-line chemotherapy for advanced/recurrent disease — practice-changing per NRG-GY018 and RUBY trials.
4. DUO-E trial: durvalumab + olaparib combination.
5. Sentinel lymph node mapping replacing full lymphadenectomy as the preferred nodal staging method.
6. Ongoing validation of de-escalation of adjuvant therapy in POLEmut tumors (excellent prognosis regardless of other adverse features).

Sentinel Lymph Node (SLN) Mapping in Endometrial Cancer

Rationale

Technique

• Injection site: Standardized cervical injection (superficial + deep, typically at 3 and 9 o'clock) is now the preferred site - superior to hysteroscopic, subserosal/fundal, or myometrial injection for reliable pelvic nodal mapping.
• Tracers:
  • Indocyanine green (ICG) with near-infrared fluorescence imaging (via robotic or laparoscopic platform) - currently the most widely used and best-performing tracer, with higher bilateral detection rates than blue dye.
  • Blue dyes (isosulfan blue, methylene blue, patent blue) - historically used, lower bilateral detection.
  • Radiolabeled technetium-99 with lymphoscintigraphy - older technique, largely superseded.
  • A recent network meta-analysis (2025) confirms ICG has the best detection performance among available tracers (Feng et al., PMID 39185991).
• Nodes are identified in the pelvic (external iliac, internal iliac, obturator, common iliac) and occasionally para-aortic/presacral basins.

The SLN Surgical Algorithm (SGO/Memorial Sloan Kettering algorithm - adopted by NCCN)

1. Peritoneal and serosal assessment ± peritoneal washings.
2. Remove all mapped SLNs and any grossly suspicious/enlarged node regardless of mapping.
3. If no SLN maps on a hemi-pelvis → mandatory side-specific (ipsilateral) pelvic lymphadenectomy on that side.
4. Para-aortic lymphadenectomy is at the surgeon's discretion, particularly for high-risk histology.

Pathologic Ultrastaging

Accuracy (Key Evidence)

• The pivotal multicenter FIRES trial demonstrated 97.2% sensitivity and 99.6% negative predictive value for the SLN algorithm compared with completion lymphadenectomy (cited in Berek & Novak's Gynecology, p. 2174).
• Detection rates: at least one SLN identified in 70-95% of cases; bilateral detection ~50-60% with blue dye, up to ~79% with ICG.
• Recent (2025) meta-analyses confirm favorable oncologic outcomes with SLN mapping even in high-intermediate and high-risk endometrial cancer, with no significant difference in recurrence or survival compared to lymphadenectomy (de Menezes et al., PMID 40460726; Zhang et al., PMID 40463879).

Management of Low-Volume Nodal Disease (Unresolved Issue)

Current Recommendations and Limitations

• NCCN allows lymph node assessment via either SLN mapping or selective/complete lymphadenectomy - it is not mandated, but SLN is now the more commonly adopted approach at experienced centers.
• Lymphadenectomy (or SLN mapping) may be omitted entirely in low-risk patients: non-invasive or minimally invasive (<50% myometrial invasion) endometrioid tumors <2 cm.
• Surgeon experience matters: a learning curve of at least ~20 supervised procedures (extrapolated from ASCO breast cancer SLN guidance) is recommended before adopting an SLN-only algorithm (SGO/SLN Working Group consensus, 2017).
• No completed phase III RCT has directly compared SLN mapping against traditional lymphadenectomy for oncologic outcomes, though real-world and meta-analytic data (2023-2025) are increasingly reassuring.

Summary Table

Molecular Classification of Endometrial Carcinoma (TCGA)

Background

The Four TCGA Molecular Subtypes

Key mechanistic points

• Endometrioid carcinomas parallel colorectal carcinoma biology: high-frequency MSI (~40% vs 11% in CRC) and POLE mutations (~7% vs 3% in CRC), with frequent WNT/CTNNB1 pathway activation - but endometrial tumors have their own distinct KRAS/CTNNB1 mutation patterns.
• Endometrial cancer shows the highest frequency of PI3K/AKT pathway mutations of any tumor type studied by TCGA.
• In hysterectomy specimens with coexisting atypical hyperplasia and carcinoma, identical PTEN/ARID1A/PIK3CA/KRAS mutations are found in both components, supporting a stepwise carcinogenesis model from hyperplasia.
• Extent of SCNA roughly correlates inversely with progression-free survival - more copy-number alterations, worse outcome.

ProMisE: Translating TCGA into Clinical Practice

1. POLE mutation testing (targeted sequencing of the exonuclease domain) → if pathogenic mutation present → POLEmut
2. If POLE wild-type → MMR IHC (MLH1, PMS2, MSH2, MSH6) → if any protein lost → MMRd
3. If MMR-intact → p53 IHC → if abnormal (overexpressed or null) → p53abn
4. If p53 wild-type pattern → NSMP (default/residual category)

Clinical Integration - FIGO 2023 and Guideline Impact

• The 2023 FIGO staging system for the first time incorporates molecular classification into anatomic staging: early-stage tumors that are POLEmut are effectively "downstaged" (excellent prognosis regardless of other risk factors), while p53abn tumors in early stage are "upstaged," denoted with an "m" suffix and subscript (e.g., Stage I_m,p53abn).
• NCCN and ESGO-ESTRO-ESP guidelines now recommend molecular classification for all endometrial cancers to refine risk-group stratification and guide adjuvant therapy:
  • POLEmut tumors → candidates for adjuvant therapy de-escalation, even with high-grade/high-risk histologic features, given their excellent prognosis.
  • p53abn tumors → treated as high-risk regardless of grade; strong candidates for adjuvant chemotherapy ± radiation.
  • MMRd tumors → intermediate prognosis; importantly predict benefit from immune checkpoint inhibitors (pembrolizumab, dostarlimab) added to first-line chemotherapy in advanced/recurrent disease (NRG-GY018, RUBY trials) - the MMRd subgroup shows the largest treatment benefit.
  • NSMP → intermediate prognosis, further risk-refined by grade, LVSI, and hormone receptor status.
• Real-world validation using comprehensive genomic profiling (FoundationOne/FoundationOneCDx) in advanced/recurrent disease confirms TP53-mutant patients have the worst time-to-next-treatment and overall survival, while POLEmut patients trend toward the best outcomes, and MSI-H/NSMP show similar intermediate outcomes.
• A recognized complication: ~5% of tumors are "multiple-classifier" (e.g., POLEmut + p53abn), requiring defined hierarchical rules (POLE status takes precedence) for classification.

Why This Matters Practically

• Identifies patients for treatment de-escalation (POLEmut) or escalation (p53abn) independent of traditional grade.
• Flags MMRd patients for Lynch syndrome workup and immunotherapy eligibility.
• Is a required/encouraged data point in the FIGO 2023 staging system and current NCCN/ESGO risk stratification tables (as discussed in the earlier management summary).

Fertility Preservation in Endometrial Carcinoma

Rationale

Eligibility Criteria (NCCN / ESGO-ESHRE-ESGE consensus)

Treatment Regimens

1. Oral progestins (most established): megestrol acetate 160-320 mg/day or medroxyprogesterone acetate 400-600 mg/day, given continuously.
2. Levonorgestrel-releasing intrauterine device (LNG-IUD): delivers high local progestin concentration directly to the endometrium with fewer systemic side effects; increasingly preferred, either alone or combined with oral progestin.
3. Hysteroscopic resection of the visible lesion followed by progestin therapy (oral or LNG-IUD): yields the highest complete response rates (90-95%) compared to progestin alone (76-78% with oral progestins, 71-73% with LNG-IUD + oral progestin) - ESGO/ESHRE/ESGE guideline.
4. Adjunct metformin: studied as an add-on (anti-estrogenic/anti-proliferative effect via AMPK pathway), with reasonable evidence for improved regression and reduced recurrence, though data are still evolving (Cochrane review 2025, PMID 40626388).
5. GnRH agonists: an alternative approach, inducing a hypoestrogenic state to promote regression, though less commonly first-line.

Response and Relapse Rates

• Overall response rate to progestin therapy in grade 1 endometrial cancer: ~76% (pooled data, median time to regression ~12 weeks); as little as 1 month of therapy may achieve response (Berek & Novak's Gynecology, p. 2146).
• Recurrence rate among responders: ~24-25%, with most recurrences within the first year after stopping/de-escalating treatment.
• Hysteroscopic resection + progestin combination: relapse rates as low as 8.7% (hyperplasia) to 11.1% (grade 1 carcinoma) at median 36 months follow-up (Casadio et al.) - generally lower than progestin-alone regimens.
• ~20-25% of patients never respond to hormonal therapy and require definitive surgery.

Monitoring Protocol

• Repeat endometrial sampling (biopsy) every 3 months (or transvaginal ultrasound as adjunct) to assess response.
• Treatment should continue for a minimum of 3-6 months before declaring failure.
• Partial responders at 6 months: may continue therapy an additional 3-6 months.
• Non-responders at 6 months (persistent disease on biopsy): counsel for hysterectomy.
• Because ~25% of atypical hyperplasia specimens harbor undiagnosed concurrent carcinoma, and because delayed recognition of progression can compromise prognosis, rigorous compliance with surveillance biopsies is essential - patients must be explicitly counseled about this risk before starting conservative management.

Definitive/Completion Surgery

• Definitive surgery (total hysterectomy ± BSO with surgical staging) is recommended:
  • After completion of childbearing
  • In non-responders or those with disease progression
  • In patients unable to conceive despite adequate response
  • In recurrence after initial response
• Ovarian preservation at the time of completion surgery can be considered case-by-case (weighing synchronous ovarian cancer risk, especially with Lynch syndrome or BRCA mutation, against benefits of preserving ovarian hormonal function).
• For patients with a strong ongoing desire for further fertility after relapse, a second course of conservative treatment may be considered selectively rather than moving straight to surgery.

Fertility and Pregnancy Outcomes

• Pregnancy rates following successful conservative treatment are meaningful but modest; assisted reproductive technology (ART) is often recommended to expedite conception once remission is confirmed, given the risk of relapse with time and the frequent coexistence of PCOS/anovulatory infertility in this population.
• Guidance on management after successful pregnancy, failure to conceive, or relapse following childbirth remains poorly standardized - no universal consensus guidelines exist for this phase; decisions are individualized based on limited retrospective data.

Key Counseling Points

1. This is not a cure but a temporizing strategy - hysterectomy remains the definitive treatment once fertility goals are met.
2. Patients must understand the risk of occult disease progression during conservative management and the importance of strict surveillance adherence.
3. Referral to a reproductive endocrinologist for fertility planning/ART should occur early, in parallel with oncologic treatment, to avoid delays that increase relapse risk.